Table Graph
      published meta-analysis   sensitivity analysis   studies

placebo in COVID-19 prophylaxis (excluding children) - Summary of results

OutcomeTE95% CInkI2ROBPub. bias 6 months symptomatic COVIDdetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 11.36 [9.02; 14.31] 11.36[9.02; 14.31]BNT162b2 phase 3 (C4591001, Polack), 2020 (REV)10%46,077NAnot evaluable confirmed Covid-19, from 1st dosedetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 5.56 [4.07; 7.58] 5.56[4.07; 7.58]BNT162b2 phase 3 (C4591001, Polack), 2020 (REV)10%42,572NAnot evaluable deathsdetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 2.00 [0.37; 10.92] 2.00[0.37; 10.92]BNT162b2 phase 3 (C4591001, Polack), 2020 (REV)10%43,252NAnot evaluable vaccine efficacy from randomization (ITT)detailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 5.56 [4.07; 7.58] 5.56[4.07; 7.58]BNT162b2 phase 3 (C4591001, Polack), 2020 (REV)10%42,572NAnot evaluable symptomatic Covid-19detailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 20.00 [9.95; 40.21] 20.00[9.95; 40.21]BNT162b2 phase 3 (C4591001, Polack), 2020 (REV)10%36,523NAnot evaluable 6 months severe COVID-19detailed resultsOut of scaleBNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 30.30 [2.16; 425.32] 30.30[2.16; 425.32]BNT162b2 phase 3 (C4591001, Polack), 2020 (REV)10%NAnot evaluable severe COVID-19 occurrencedetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 4.00 [0.18; 89.91] 4.00[0.18; 89.91]BNT162b2 phase 3 (C4591001, Polack), 2020 (REV)10%42,573NAnot evaluable vaccine efficacy after dose 1 (and before dose 2)detailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 2.10 [1.41; 3.14] 2.10[1.41; 3.14]BNT162b2 phase 3 (C4591001, Polack), 2020 (REV)10%43,355NAnot evaluable related AE (TRAE)detailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 0.20 [0.19; 0.22] 0.20[0.19; 0.22]BNT162b2 phase 3 (C4591001, Polack), 2020 (REV)10%43,252NAnot evaluable related SAE (TRSAE)detailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 0.12 [0.01; 2.36] 0.12[0.01; 2.36]BNT162b2 phase 3 (C4591001, Polack), 2020 (REV)10%43,252NAnot evaluable serious adverse eventsdetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 0.88 [0.68; 1.14] 0.88[0.68; 1.14]BNT162b2 phase 3 (C4591001, Polack), 2020 (REV)10%43,252NAnot evaluable adverse eventsdetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 0.38 [0.36; 0.40] 0.38[0.36; 0.40]BNT162b2 phase 3 (C4591001, Polack), 2020 (REV)10%43,252NAnot evaluable life-threatening SAEdetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 1.09 [0.61; 1.98] 1.09[0.61; 1.98]BNT162b2 phase 3 (C4591001, Polack), 2020 (REV)10%43,252NAnot evaluable severe adverse eventsdetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 0.58 [0.47; 0.71] 0.58[0.47; 0.71]BNT162b2 phase 3 (C4591001, Polack), 2020 (REV)10%43,252NAnot evaluable appendicitisdetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 0.50 [0.15; 1.66] 0.50[0.15; 1.66]BNT162b2 phase 3 (C4591001, Polack), 2020 (REV)10%43,448NAnot evaluable Bell's palsydetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 0.13 [0.01; 2.37] 0.13[0.01; 2.37]BNT162b2 phase 3 (C4591001, Polack), 2020 (REV)10%37,586NAnot evaluable hypersensitivity, all termsdetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 0.46 [0.18; 1.21] 0.46[0.18; 1.21]BNT162b2 phase 3 (C4591001, Polack), 2020 (REV)10%43,252NAnot evaluable immediate allergic reactiondetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 1.00 [0.02; 50.38] 1.00[0.02; 50.38]BNT162b2 phase 3 (C4591001, Polack), 2020 (REV)10%43,448NAnot evaluable lymphadenopathy, anydetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 0.09 [0.04; 0.22] 0.09[0.04; 0.22]BNT162b2 phase 3 (C4591001, Polack), 2020 (REV)10%37,586NAnot evaluable musculoskeletal and connective tissue disorders, anydetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 0.27 [0.24; 0.31] 0.27[0.24; 0.31]BNT162b2 phase 3 (C4591001, Polack), 2020 (REV)10%37,586NAnot evaluable local adverse reaction, any, dose 1detailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 0.04 [0.04; 0.05] 0.04[0.04; 0.05]BNT162b2 phase 3 (C4591001, Polack), 2020 (REV)10%8,183NAnot evaluable local adverse reaction, any, dose 2detailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 0.04 [0.04; 0.05] 0.04[0.04; 0.05]BNT162b2 phase 3 (C4591001, Polack), 2020 (REV)10%7,507NAnot evaluable systemic adverse reaction, any, dose 1detailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 0.61 [0.56; 0.67] 0.61[0.56; 0.67]BNT162b2 phase 3 (C4591001, Polack), 2020 (REV)10%8,183NAnot evaluable systemic adverse reaction, any, dose 2detailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 0.22 [0.20; 0.24] 0.22[0.20; 0.24]BNT162b2 phase 3 (C4591001, Polack), 2020 (REV)10%7,507NAnot evaluable0.020.01.0relative treatment effectwww.metaEvidence.org2024-05-23 15:47 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 89 - treatments: 650 - roots T: 650

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons